Heron Therapeutics (HRTX) Stock Price, Quote & News

Company Profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed na...

Industry: Biotechnology

Sector: Healthcare

Phone: (858) 251-4400

Website: www.herontx.com

Address:

100 Regency Forest Drive, Suite 300, Cary, United States

Braddog Jul. 16 at 8:45 PM

$HRTX Day after Day…… Week after Week…… Month after Month…… Year after Year….. And a Decade…… Horrible long term investment

0 · Reply

brunoq14 Jul. 16 at 6:47 PM

$HRTX https://www.monash.edu/news/articles/antinausea-medication-linked-to-higher-survival-rates-in-women-with-triple-negative-breast-cancer

1 · Reply

brunoq14 Jul. 16 at 6:21 PM

$HRTX Association of aprepitant with cancer survival

0 · Reply

brunoq14 Jul. 16 at 6:06 PM

$HRTX https://academic.oup.com/jnci/advance-article/doi/10.10913/jnci/djaf178/8196554?login=false

0 · Reply

jacksonjohn750 Jul. 16 at 3:56 PM

$HRTX sold a bunch today..

2 · Reply

brunoq14 Jul. 16 at 2:20 PM

$HRTX Aponvie apparently may be effective against cancer. But no one seems to be interested.yet.

1 · Reply

brunoq14 Jul. 16 at 1:58 PM

$HRTX "Anti-nausea drug lowers risk of death from aggressive breast cancer by 39%" Yup, it's aprepitant.

0 · Reply

brunoq14 Jul. 16 at 12:39 PM

$HRTX Numerous articles starting to show up about possibly repurposing aprepitant as a cancer therapy, based on a European trial.

1 · Reply

brunoq14 Jul. 16 at 12:30 PM

$HRTX https://www.newatlas.com/disease/aprepitant-anti-emetic-breast-cancer-survival

0 · Reply

brunoq14 Jul. 16 at 10:56 AM

$HRTX Has anyone here read an article about aprepitant being linked in a study to a lower risk of developing cancer and a lower risk of cancer caused death over a given time period zynrelef?

0 · Reply

Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025

May 6, 2025, 11:38 AM EDT - 2 months ago

Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:45 AM EDT - 2 months ago

Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

May 6, 2025, 7:30 AM EDT - 2 months ago

Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

Apr 28, 2025, 6:55 PM EDT - 2 months ago

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

Apr 22, 2025, 4:05 PM EDT - 3 months ago

Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

Feb 27, 2025, 12:07 PM EST - 4 months ago

Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:45 AM EST - 4 months ago

Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

Feb 13, 2025, 4:20 PM EST - 5 months ago

Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025

Dec 23, 2024, 4:05 PM EST - 7 months ago

Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

Dec 4, 2024, 3:01 PM EST - 8 months ago

Relief For Heron Therapeutics After The Court Win On Cinvanti

Dec 3, 2024, 4:36 PM EST - 8 months ago

U.S. District Court Upholds Validity of CINVANTI® Patents

Nov 12, 2024, 11:45 AM EST - 8 months ago

Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:55 AM EST - 8 months ago

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

Nov 4, 2024, 5:00 PM EST - 9 months ago

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Oct 29, 2024, 4:05 PM EDT - 9 months ago

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

Oct 10, 2024, 4:08 PM EDT - 9 months ago

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Sep 25, 2024, 8:00 AM EDT - 10 months ago

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Sep 3, 2024, 8:00 AM EDT - 11 months ago

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Aug 9, 2024, 10:14 AM EDT - 1 year ago

Heron Therapeutics, Inc., (HRTX) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

Jul 30, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

Jul 15, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

May 29, 2024, 8:05 AM EDT - 1 year ago

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

May 7, 2024, 2:38 PM EDT - 1 year ago

Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript

May 7, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates

Apr 24, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Apr 16, 2024, 4:24 PM EDT - 1 year ago

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Apr 11, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 12, 2024, 10:35 PM EDT - 1 year ago

Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

Feb 28, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

Feb 17, 2024, 1:54 AM EST - 1 year ago

Heron Therapeutics Is Out Of Survival Mode

Jan 23, 2024, 8:00 PM EST - 1 year ago

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Jan 7, 2024, 5:00 PM EST - 1 year ago

Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain

Dec 29, 2023, 3:14 PM EST - 1 year ago

Heron Therapeutics Gets Back On Track

Nov 30, 2023, 9:00 AM EST - 1 year ago

Why Heron Therapeutics Is A Compelling Buy Into 2024

Nov 14, 2023, 7:45 PM EST - 1 year ago

Heron Therapeutics, Inc. (HRTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 4:05 PM EST - 1 year ago

Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

Nov 7, 2023, 4:05 PM EST - 1 year ago

Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023

Aug 14, 2023, 6:48 PM EDT - 2 years ago

Heron Therapeutics, Inc. (HRTX) Q2 2023 Earnings Call Transcript

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates

Aug 7, 2023, 4:05 PM EDT - 2 years ago

Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

Jul 28, 2023, 3:57 PM EDT - 2 years ago

Heron Therapeutics: Restructuring Brings About A New Dawn

Jul 24, 2023, 9:02 AM EDT - 2 years ago

Heron Therapeutics Announces Cost Reduction Plan and Restructuring

Jul 24, 2023, 9:00 AM EDT - 2 years ago

Heron Therapeutics Announces $30 Million Private Placement Financing

HTGC

Jun 23, 2023, 4:05 PM EDT - 2 years ago

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Jun 12, 2023, 9:00 AM EDT - 2 years ago

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer

Braddog Jul. 16 at 8:45 PM

$HRTX Day after Day…… Week after Week…… Month after Month…… Year after Year….. And a Decade…… Horrible long term investment

0 · Reply

brunoq14 Jul. 16 at 6:47 PM

$HRTX https://www.monash.edu/news/articles/antinausea-medication-linked-to-higher-survival-rates-in-women-with-triple-negative-breast-cancer

1 · Reply

brunoq14 Jul. 16 at 6:21 PM

$HRTX Association of aprepitant with cancer survival

0 · Reply

brunoq14 Jul. 16 at 6:06 PM

$HRTX https://academic.oup.com/jnci/advance-article/doi/10.10913/jnci/djaf178/8196554?login=false

0 · Reply

jacksonjohn750 Jul. 16 at 3:56 PM

$HRTX sold a bunch today..

2 · Reply

brunoq14 Jul. 16 at 2:20 PM

$HRTX Aponvie apparently may be effective against cancer. But no one seems to be interested.yet.

1 · Reply

brunoq14 Jul. 16 at 1:58 PM

$HRTX "Anti-nausea drug lowers risk of death from aggressive breast cancer by 39%" Yup, it's aprepitant.

0 · Reply

brunoq14 Jul. 16 at 12:39 PM

$HRTX Numerous articles starting to show up about possibly repurposing aprepitant as a cancer therapy, based on a European trial.

1 · Reply

brunoq14 Jul. 16 at 12:30 PM

$HRTX https://www.newatlas.com/disease/aprepitant-anti-emetic-breast-cancer-survival

0 · Reply

brunoq14 Jul. 16 at 10:56 AM

$HRTX Has anyone here read an article about aprepitant being linked in a study to a lower risk of developing cancer and a lower risk of cancer caused death over a given time period zynrelef?

0 · Reply

Smartynow Jul. 16 at 3:49 AM

$HRTX shorts are trying to sell the idea that the company is doing bad go back to the 1Q report estimated revenue 153 - 163 m looks like they will deliver 80 or more for 1+ 2 Q the 3 + 4 Q should be even better looks like they are meeting the high estimated numbers or even better i would buy anything $ 2-3 now

0 · Reply

Braddog Jul. 15 at 9:05 PM

$HRTX So I’m having surgery this afternoon. It’s minor surgery and I asked the surgeon if he has heard of Zyn. And he has NOT heard of Zyn. It just proves to me that Heron doesn’t have the capital, the $$$, the what it takes, to make Zyn a blockbuster. We have BB debt upcoming and need a solution with no dilution. The dollar cost opportunity is so depressing.

4 · Reply

YosemiteSammm Jul. 15 at 8:59 PM

$HRTX been holding this turd for a year and a half. Shorts do not let us hold gains for nothing.

0 · Reply

Rambogator Jul. 15 at 5:32 PM

$HRTX I think the only people making money on HRTX is the management team. The quietest rollout of a fast tracked drug ever. So disappointing, hopefully CC is making a deal in the background, I think that’s our only hope at this point.

0 · Reply

bambus3001 Jul. 14 at 8:41 PM

$HRTX wieder knock out zum Schluss,dicker Umsatz .denke diese woche gehts los mit der Wende.!!

1 · Reply

chance111 Jul. 14 at 2:57 PM

$HRTX It is almost a certainty that this will be manipulated down over the next few weeks leading up to earnings. With a positive report, price will take off. Don't be concerned when this goes down that there was leak indicating bad earnings. Anyone who has been in this stock for a long period of time knows about the manipulation. I hope I am correct!

2 · Reply

Judykay Jul. 14 at 2:24 PM

$KODK Are you watching my frens at $HRTX $IBRX

1 · Reply

Smartynow Jul. 14 at 12:12 PM

$HRTX based on those numbers we should be around 41 millions for the 2 Q also looks like Zyn 1200 ml is selling alot more and they are looking to get more of the market share even if it ’s going to effect the total amount of $$$

0 · Reply

Shooter40 Jul. 12 at 12:39 AM

$HRTX Zyn grew 65% in june versus june 2024. Apo had monster growth

0 · Reply

Braddog Jul. 11 at 8:59 PM

$HRTX Aponvie and Cinvanti Aponvie appears to be growing.

1 · Reply

Braddog Jul. 11 at 8:58 PM

$HRTX Zynrelef This is sad and pathetic

3 · Reply

Judykay Jul. 11 at 6:04 PM

$KODK $IBRX $HRTX My frens in these spaces. Take a look through the Kodak thread. Pivot is on into pharmaceuticals @defineme44 Yahoo board says Berkshire took a stake in KODK.

1 · Reply

Market Cap	323.44M
Revenue (ttm)	144.29M
Net Income (ttm)	-13.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-9.41%
Debt to Equity Ratio	-0.89

Volume	1,048,948
Avg Vol	1,673,886
Day's Range	N/A - N/A
Shares Out	152.56M
Stochastic %K	5%
Beta	1.18
Analysts	Strong Sell
Price Target	$6.25